Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a monocentric, two-arm, non-randomised, non-blinded, historically controlled,
interventional trial. The purpose of this trial is to investigate the effect of
model-informed infliximab dose de-escalation on the infliximab exposure and therapeutic
outcome as compared to standard dose de-escalation in patients with inflammatory bowel
diseases.